Studies gut bacteria in people with spondyloarthritis or rheumatoid arthritis
Compares gut bacteria samples from adults with these joint diseases and healthy volunteers.
Plain-language title generated from the registry record
Registry title: Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
Key facts
- Where
- Boulogne-Billancourt, FranceSee the site
Where in France
- Service de Rhumatologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de ParisBoulogne-Billancourt, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT04292067
- Record updated
- 15 June 2025
- Original description
The primary objective of the study aims to compare the biodiversity of intestinal microbiota between spondylarthritis (SPA) or rheumatoid arthritis (RA) patients and healthy volunteers, by microbiota DNA sequencing in order to further and respond the prior results, which suggested that there is a specific dysbiosis for each of the 2 diseases. A comparative analysis will allow to identify the biomarkers of the specific bacteria.Read full original descriptionShow less
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
The primary objective of the study aims to compare the biodiversity of intestinal microbiota between spondylarthritis (SPA) or rheumatoid arthritis (RA) patients and healthy volunteers, by microbiota DNA sequencing in order to further and respond the prior results, which suggested that there is a specific dysbiosis for each of the 2 diseases. A comparative analysis will allow to identify the biomarkers of the specific bacteria.
Inclusion: Patients:; Patient ⩾ 18 years; Diagnosed as spondyloarthritis (SpA) according ASAS classification, or rheumatoid polyarthritis according ACR/EULAR; Affiliated to a social security scheme; Have signed the written informed consent form; Healthy control subjects:; Adult women and men; Subjet free of chronic pathology; Affiliated to a social security scheme; Have signed the written informed consent form.
Exclusion: Have taken antibiotic 1 month prior to inclusion or digestive coloscopy 6 months prior inclusion; Patients had have participated in the prior study Microbiart; Healthy control subjects:; Subjects had have participated in the prior study Microbiart; Subjects < 18 years; Patients:; Patients unable to understand the proposed study and/or sign a informed consent form; Pregnant women or breast feeding women; Patient ⩾ 18 years; Patients under guardianship or curatorship; Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome; Foreign patients under french AME scheme; Subjects unable to understand the proposed study and/or sign a informed consent form; Pregnant women or breast feeding women; Subjects under guardianship or curatorship; Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome; Refusal of subjects to participate to the study; Foreign patients under french AME scheme.